Why the study?
Accurate cardiovascular risk assessment and management strategies before non-cardiac surgery are essential to optimize patient outcomes and guide clinical decision-making.
Answers are grounded in this paper and cite their sources.
Summarizes the core recommendations of the 2022 ESC guidelines for the cardiovascular evaluation and management of patients prior to and following non-cardiac surgery.
Accurate medical history and clinical examination before non-cardiac surgery (NCS) is the first step in the risk assessment. Patients’ age (cut-off of 65 years), presence or absence of cardiovascular (CV) risk factors, and established CV disease (CVD) determine patient-related risk and necessity of further work-up before NCS. Key Commandments of the 2022 ESC guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. ACS, acute coronary syndrome; ECG, electrocardiogram; hs cTnT/I, high-sensitivity cardiac troponin T/I; NCS, non-cardiac surgery; PCI, percutaneous coronary intervention; PE, pulmonary emboli; POAF, post-operative atrial fibrillation. In patients who have known CVD or CV risk factors (including age ≥65 years), electrocardiogram (ECG) and measurement of biomarkers are recommended. High-sensitivity cardiac troponin T/I enables both ruling-out acute myocardial injury before NCS and accurate diagnosis of peri-operative myocardial injury (PMI) on the day(s) after surgery. Its measurement is recommended before intermediate- and high-risk NCS, as well as at 24 and 48 h afterwards. Transthoracic echocardiography is recommended in patients with poor functional capacity and/or high BNP/proBNP, or if murmurs are detected before NCS. If time allows, it is recommended to optimize guideline-recommended treatment of CVD and CV risk factors before NCS. In general, it is recommended to delay elective NCS until 6 months after elective PCI and 12 months after an ACS. In case of time-sensitive NCS, it is recommended to delay surgery until a minimum of 1 month (after elective PCI) or 3 months (ACS at index PCI or other high-ischaemic risk features) of DAPT treatment has been given. Bridging of oral anticoagulation therapy is not recommended in patients with low/moderate thrombotic risk undergoing NCS. It is recommended that decisions on thromboprophylaxis are based on individual and procedural-specific risk factors. It is recommended to measure haemoglobin pre-operatively in patients scheduled for intermediate/high-risk NCS, and to treat anaemia in advance of NCS. We recommend using the same indications for invasive coronary angiography and revascularization preoperatively as in the non-surgical setting. For patients scheduled for elective intermediate- or high-risk NCS, aortic valve intervention is recommended for symptomatic severe aortic valve stenosis. In severe mitral regurgitation, mitral valve intervention should be considered when symptoms persist despite optimal guideline-recommended treatment. It is recommended to have high awareness of peri-operative CV complications including surveillance for PMI. PMI is detected by elevation of high-sensitivity cardiac troponin T/I. A systematic work-up of PMI is required to identify the underlying pathophysiology and therapy.
No takes yet. Share an insight, caveat, or question.
Mehilli et al. (2022) conducted a review in Cardiovascular assessment and management in non-cardiac surgery. 2022 ESC Guidelines was evaluated. The 2022 ESC guidelines summarize ten key commandments for cardiovascular assessment before non-cardiac surgery, emphasizing preoperative ECG, biomarker testing, and optimal timing after PCI or ACS.
Synapse has enriched 10 related papers. Consider them for comparative context: